Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.A. Ghofrani, I.H. Osterloh, F. Grimminger.
Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond.
Nat Rev Drug Discov., 5 (2006), pp. 689-702
[2.]
L.S. Shekerdemian, H.B. Ravn, D.J. Penny.
Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension.
Am J Respir Crit Care Med., 165 (2002), pp. 1098-1102
[3.]
B.K. Sastry, C. Narasimhan, N.K. Reddy, B.S. Raju.
Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study.
J Am Coll Cardiol., 43 (2004), pp. 1149-1153
[4.]
E. Michelakis, W. Tymchak, D. Lien, L. Webster, K. Hashimoto, S. Archer.
Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide.
Circulation, 105 (2002), pp. 2398-2403
[5.]
J.J. Lepore, A. Maroo, N.L. Pereira, L.C. Ginns, G.W. Dec, W.M. Zapol, et al.
Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension.
Am J Cardiol, 90 (2002), pp. 677-680
[6.]
I.V. Turko, S.A. Ballard, S.H. Francis, J.D. Corbin.
Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.
Mol Pharmacol., 56 (1999), pp. 124-130
[7.]
J.D. Corbin, S.H. Francis.
Pharmacology of phosphodiesterase-5 inhibitors.
Int J Clin Pract., 56 (2002), pp. 453-459
[8.]
L. Moreno, B. Losada, A. Cogolludo, F. Lodi, C. Lugnier, E. Villamor, et al.
Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: Activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway.
Pediatr Res., 56 (2004), pp. 563-570
[9.]
L.S. Shekerdemian, H.B. Ravn, D.J. Penny.
Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome.
Pediatr Res., 55 (2004), pp. 413-418
[10.]
G.W. Mikhail, S.K. Prasad, W. Li, P. Rogers, A.H. Chester, S. Bayne, et al.
Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: Acute and mid-term effects.
Eur Heart J., 25 (2004), pp. 431-436
[11.]
H.A. Ghofrani, R. Wiedemann, F. Rose, R.T. Schermuly, H. Olschewski, N. Weissmann, et al.
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial.
Lancet, 360 (2002), pp. 895-900
[12.]
M.E. García, R.I. Ibarra del, J.L. Pérez Navero, M.I. Tejero, J.F. Expósito Montes, D.L. Suárez.
Sildenafil in the treatment of pulmonary hypertension.
An Pediatr (Barc), 59 (2003), pp. 110-113
[13.]
G.N. Fernández, F.A. Rodríguez, R.J. Jerez, S.M. Parrondo Garrido, M.L. Martínez.
Oral sildenafil: A promising drug for persistent neonatal pulmonary hypertension.
An Pediatr (Barc), 61 (2004), pp. 567-568
[14.]
A.A. Karatza, I. Narang, M. Rosenthal, A. Bush, A.G. Magee.
Treatment of primary pulmonary hypertension with oral sildenafil.
Respiration, 71 (2004), pp. 192-194
[15.]
R.L. Keller, S.E. Hamrick, J.A. Kitterman, J.R. Fineman, S. Hawgood.
Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia.
Pediatr Crit Care Med., 5 (2004), pp. 184-187
[16.]
P.M. Filan, P.N. McDougall, L.S. Shekerdemian.
Combination pharmacotherapy for severe neonatal pulmonary hypertension.
J Paediatr Child Health, 42 (2006), pp. 219-220
[17.]
D.E. Simiyu, C. Okello, E.G. Nyakundi, A.H. Tawakal.
Sildenafil in management of persistent pulmonary hypertension of the newborn: Report of two cases.
East Afr Med J., 83 (2006), pp. 337-340
[18.]
Z. Kecskes, A. Kent, G. Reynolds.
Treatment of pulmonary hypertension with sildenafil in a neonate with spondyloepiphyseal dysplasia congenita.
J Matern Fetal Neonatal Med., 19 (2006), pp. 579-582
[19.]
M. Chaudhari, M. Vogel, C. Wright, J. Smith, S.G. Haworth.
Sildenafil in neonatal pulmonary hypertension due to impaired alveolarisation and plexiform pulmonary arteriopathy.
Arch Dis Child Fetal Neonatal Ed., 90 (2005), pp. F527-F528
[20.]
P. Namachivayam, U. Theilen, W.W. Butt, S.M. Cooper, D.J. Penny, L.S. Shekerdemian.
Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children.
Am J Respir Crit Care Med., 174 (2006), pp. 1042-1047
[21.]
R.L. Keller, P. Moore, D. Teitel, S. Hawgood, J. McQuitty, J.R. Fineman.
Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy.
Pediatr Crit Care Med., 7 (2006), pp. 589-594
[22.]
P. Pham, A. Hoyer, R. Shaughnessy, Y.M. Law.
A novel approach incorporating sildenafil in the management of symptomatic neonates with Ebstein's anomaly.
Pediatr Cardiol., 27 (2006), pp. 614-617
[23.]
H. Baquero, A. Soliz, F. Neira, M.E. Venegas, A. Sola.
Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study.
Pediatrics, 117 (2006), pp. 1077-1083
[24.]
M.C. Walsh, E.K. Stork.
Persistent pulmonary hypertension of the newborn Rational therapy based on pathophysiology.
Clin Perinatol., 28 (2001), pp. 609-627
[25.]
J.N. Travadi, S.K. Patole.
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: A review.
Pediatr Pulmonol., 36 (2003), pp. 529-535
[26.]
S.A. Lorch, A. Cnaan, K. Barnhart.
Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn.
Pediatrics, 114 (2004), pp. 417-426
[27.]
J.P. Kinsella, S.H. Abman.
Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia.
J Pediatr., 136 (2000), pp. 717-726
[28.]
L.K. Kelly, N.F. Porta, D.M. Goodman, C.L. Carroll, R.H. Steinhorn.
Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide.
J Pediatr., 141 (2002), pp. 830-832
[29.]
A. Saygili, B. Canter, E. Iriz, S. Kula, F.S. Tunaoglu, R. Olgunturk, et al.
Use of sildenafil with inhaled nitric oxide in the management of severe pulmonary hypertension.
J Cardiothorac Vasc Anesth., 18 (2004), pp. 775-776
[30.]
H.A. Ghofrani, J. Pepke-Zaba, J.A. Barbera, R. Channick, A.M. Keogh, M.A. Gómez-Sánchez, et al.
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
J Am Coll Cardiol., 43 (2004), pp. 68-72
[31.]
W.D. Carroll, R. Dhillon.
Sildenafil as a treatment for pulmonary hypertension.
Arch Dis Child, 88 (2003), pp. 827-828
[32.]
F. Ichinose, J. Erana-García, J. Hromi, Y. Raveh, R. Jones, L. Krim, et al.
Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension.
Crit Care Med., 29 (2001), pp. 1000-1005
[33.]
S.L. Katz, I. Adatia, E. Louca, K. Leung, T. Humpl, J.T. Reyes, et al.
Nebulized therapies for childhood pulmonary hypertension: An in vitro model.
Pediatr Pulmonol., 41 (2006), pp. 666-673
[34.]
J. Weimann, R. Ullrich, J. Hromi, Y. Fujino, M.W. Clark, K.D. Bloch, et al.
Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
Anesthesiology, 92 (2000), pp. 1702-1712
[35.]
A.M. Atz, D.L. Wessel.
Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.
Anesthesiology, 91 (1999), pp. 307-310
[36.]
S. Erickson, J. Reyes, D. Bohn, I. Adatia.
Sildenafil (viagra) in childhood and neonatal pulmonary hypertension.
J Am Coll Cardiol., 39 (2002), pp. 402A
[37.]
N. Galie, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, D. Badesch, et al.
Sildenafil citrate therapy for pulmonary arterial hypertension.
N Engl J Med., 353 (2005), pp. 2148-2157
[38.]
T.P. Singh, M. Rohit, A. Grover, S. Malhotra, R. Vijayvergiya.
A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
Am Heart J., 151 (2006), pp. 851-855
[39.]
S. Roizenblatt, C. Guilleminault, D. Poyares, F. Cintra, A. Kauati, S. Tufik.
A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea.
Arch Intern Med., 166 (2006), pp. 1763-1767
[40.]
B.P. Madden, M. Allenby, T.K. Loke, A. Sheth.
A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.
Vascul Pharmacol., 44 (2006), pp. 372-376
[41.]
P.K. Ryhammer, L.S. Shekerdemian, D.J. Penny, H.B. Ravn.
Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets.
Pediatr Res., 59 (2006), pp. 762-766
[42.]
P. Fesler, A. Pagnamenta, B. Rondelet, F. Kerbaul, R. Naeije.
Effects of sildenafil on hypoxic pulmonary vascular function in dogs.
J Appl Physiol., 101 (2006), pp. 1085-1090
[43.]
E. Haase, D.L. Bigam, O. Cravetchi, P.Y. Cheung.
Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets.
Shock, 26 (2006), pp. 99-106
[44.]
H.S. Shin, S.K. Bae, M.G. Lee.
Pharmacokinetics of sildenafil after intravenous and oral administration in rats: Hepatic and intestinal first-pass effects.
Int J Pharm., 320 (2006), pp. 64-70
[45.]
M.C. De Rosalmeida, L.D. Saraiva, G. Da Jr, B.B. Ivo, M.V. Da Nobrega, F.A. Gondim, et al.
Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats.
Dig Dis Sci., 48 (2003), pp. 2064-2068
[46.]
Y.W. Wang, H.C. Lin, Y.Y. Yang, M.C. Hou, S.D. Lee.
Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.
J Gastroenterol., 41 (2006), pp. 593-597
[47.]
I. Goldstein, T.F. Lue, H. Padma-Nathan, R.C. Rosen, W.D. Steers, P.A. Wicker.
Oral sildenafil in the treatment of erectile dysfunction Sildenafil Study Group.
N Engl J Med., 338 (1998), pp. 1397-1404
[48.]
D. Behn, M.J. Potter.
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
Invest Ophthalmol Vis Sci., 42 (2001), pp. 523-527
[50.]
C.S. Marsh, B. Marden, R. Newsom.
Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension.
Br J Ophthalmol., 88 (2004), pp. 306-307
[51.]
R. Vidavalur, S.V. Penumathsa, L. Zhan, M. Thirunavukkarasu, N. Maulik.
Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor.
Vascul Pharmacol., 45 (2006), pp. 91-95
[52.]
F.W. Fraunfelder, H.D. Pomeranz, R.A. Egan.
Nonarteritic anterior ischemic optic neuropathy and sildenafil.
Arch Ophthalmol., 124 (2006), pp. 733-734
[53.]
S. Gedik, G. Yilmaz, Y.A. Akova.
Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient.
Eye, 21 (2007), pp. 129-130
[54.]
T.I. Metelitsina, J.E. Grunwald, J.C. DuPont, G.S. Ying, C. Liu.
Effect of viagra on retinal vein diameter in AMD patients.
Exp Eye Res, 83 (2006), pp. 128-132
[55.]
M.L. Lemus-Varela, A. Sola, B.C. Gómez-Meda, A.L. Zamora-Pérez, M.L. Ramos-Ibarra, C.M. Batista-González, et al.
Oral sildenafil citrate lacks genotoxicity and cytotoxicity in a primate model: Callithrix jacchus.
J Perinatol., 26 (2006), pp. 423-427
[56.]
V. Volke, G. Wegener, E. Vasar.
Augmentation of the NO-cGMP cascade induces anxiogenic-like effect in mice.
J Physiol Pharmacol., 54 (2003), pp. 653-660
[57.]
H.A. Milman, S.B. Arnold.
Neurologic, psychological, and aggressive disturbances with sildenafil.
Ann Pharmacother., 36 (2002), pp. 1129-1134
[58.]
M. Wang, J. Urenjak, E. Fedele, T.P. Obrenovitch.
Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
Biochem Pharmacol., 67 (2004), pp. 1619-1627
[59.]
C.S. Patil, S.V. Padi, V.P. Singh, S.K. Kulkarni.
Sildenafil induces hyperalgesia via activation of the NO-cGMP pathway in the rat neuropathic pain model.
Inflammopharmacology, 14 (2006), pp. 22-27
[60.]
S. Brenner.
Sildenafil increases cerebrovascular reactivity: A transcranial Doppler study.
Neurology, 66 (2006), pp. 1455-1456
[61.]
L.F. De, O. Bruera, J. Leston, J. Ferreiro.
Cluster headache attack due to sildenafil intake.
Cephalalgia, 26 (2006), pp. 617-619
[62.]
M. Habek, D. Petravic.
Stroke – An adverse reaction to sildenafil.
Clin Neuropharmacol., 29 (2006), pp. 165-167
[63.]
J. Oliver, D.J. Webb.
Sildenafil for “blue babies” Such unlicensed drug use might be justified as last resort.
BMJ, 325 (2002), pp. 1174
[64.]
Baquero H, Sola A, Lantos J, Neira F. A reality out of sight 2006 [cited 2006 Oct 12] Available from http://pediatrics.aap-publications.org/cgi/eletters/117/4/1077
[65.]
J. Killen, C. Grady, G.K. Folkers, A.S. Fauci.
Ethics of clinical research in the developing world.
Nat Rev Immunol., 2 (2002), pp. 210-215
Copyright © 2007. Asociación Española de Pediatría
